Home Tags EHA

Tag: EHA

IMGN779 Demonstrates Favorable Safety Profile with repeat Dosing and no Dose-limiting...

The first-in-human data demonstrate the safety and tolerability of IMGN779, being developed by ImmunoGen, across seven dose levels, with no dose limiting toxicities (DLTs),...

Study Shows 76% Objective Response Rate in Newly Diagnosed Acute Myeloid...

Phase I clinical data from a study evaluating vadastuximab talirine, also known as SGN-CD33A or 33A in combination with hypomethylating agents (HMAs; azacitidine, decitabine) in...

Amgen Presents TOWER Study During 21st Congress of the European Hematology...

During the upcoming 21st Congress of the European Hematology Association (EHA), the premier hematology congress in Europe being held June 9-12, 2016, in Copenhagen, Denmark, Amgen...
European Hematology Association

Preclinical Data of Novel Antibody-drug Conjugate IMGN779 Demonstrates Potent Activity Against...

Results from a preclinical trial shows that IMGN779, a novel, DNA-alkylating, anticancer therapeutics based on ImmunoGen, Inc, antibody-drug conjugates (ADC) technology, shows potent activity against CD33-expressing acute myeloid leukemia cells,including leukemic stem cells, while sparing normal cells.

DOWNLOAD